Skip to Content

Quintanrix

Active Substance: diphtheria toxoid / tetanus toxoid / inactivated Bordetella pertussis / hepatitis B surface antigen (rDNA) / Haemophilus influenzae type b polysaccharide
Common Name: diphtheria, tetanus, pertussis (whole cell), hepatitis B (rDNA) and Haemophilus influenzae type B conjugate vaccine (absorbed)
ATC Code: J07CA10
Marketing Authorisation Holder: GlaxoSmithKline Biologicals S.A.
Active Substance: diphtheria toxoid / tetanus toxoid / inactivated Bordetella pertussis / hepatitis B surface antigen (rDNA) / Haemophilus influenzae type b polysaccharide
Status: Withdrawn
Authorisation Date: 2005-02-17
Therapeutic Area: Meningitis, Haemophilus Hepatitis B Diphtheria Whooping Cough Immunization Tetanus
Pharmacotherapeutic Group: Vaccines

Therapeutic Indication

Quintanrix is indicated for primary immunisation of infants (during the first year of life) against diphtheria, tetanus, pertussis, hepatitis B and invasive disease caused by Haemophilus influenzae type b and for booster immunisation of young children during the second year of life.
The use of Quintanrix should be determined on the basis of official recommendations.

The marketing authorisation for Quintanrix has been withdrawn at the request of the marketing authorisation holder

Source: European Medicines Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide